<DOC>
	<DOCNO>NCT01026727</DOCNO>
	<brief_summary>This phase 2b study design ass long-term efficacy ( 24 week ) MPC-4326 combination 2-3 drug optimize background regimen ( OBR ) relative efficacy 3-4 antiretroviral ( ARV ) regimen treatment experience , HIV-1 infect subject .</brief_summary>
	<brief_title>A Study Assess Long-term Efficacy ( 24 Weeks ) MPC-4326 Combination With 2-3 Drug OBR Relative Efficacy 3-4 Drug ARV Regimen Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy</brief_title>
	<detailed_description>Standard antiretroviral therapy treatment HIV/AIDS , effective vary lengths time , render inadequate viral suppression emergence drug resistant virus , include resistance entire mechanistic class drug . Thus , exist significant unmet medical need new highly potent antiretroviral agent novel mechanisms action . The novel mechanism action MPC-4326 suggest MPC-4326 may utility treatment HIV-1 infect patient fail current regimen due development drug resistance .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Voluntarily consent participate study ( sign Informed Consent Form ) , able understand study procedures complete study . 2 . Be least 18 year age time screen . 3 . Have screen plasma HIV1 RNA value ≥ 1,000 copies/mL 4 . Be receive ARV regimen contain least 3 drug unchanged least 8 week prior initial screening . 5 . Have least two fully active ARVs ( exclusive MPC4326 ) determine 'maximal response ' vircoTYPE assay ; R5 tropism test ( applicable ) ; treatment history ( e.g. , naïve enfuvirtide integrase inhibitor ) combine regimen contain maximum four ARVs 34d ARV regimen three ARVs 23drug OBR combine MPC4326 . 6 . Two NRTIs allow fullyactive antiretroviral agent 34drug ARV regimen 23drug OBR 7 . Must wild type Gag position 370 ( i.e. , polymorphisms 370 ) 8 . Have resistance least one agent three 'classic ' ARV drug class ( NRTI , NNRTI , PI ) include document evidence resistance prior resistance test . 9 . Females childbearing potential must agree use two form contraception time screen 90 day completion dosing.Surfactanttype spermicide gel contraceptive foam recommend , increase rate HIV transmission . 1 . Be pregnant breast feed 2 . Presence significant acute illness ( determined investigator ) within 14 day study entry . 3 . Presence AIDSrelated opportunistic infection ( Category C accord CDC Classification System HIV1 Infection , 1993 Revised Version ) unstable Investigator 's opinion diagnose 30 day prior study entry ( i.e. , Run Period Day 1 ) . 4 . A history cerebrovascular accident transient ischemic attack . 5 . Subjects follow laboratory parameter within 14 day prior first dose study drug : 1 . Hemoglobin &lt; 10 g/dL men &lt; 9 g/dL woman 2 . Absolute neutrophil count &lt; 1000/mm3 3 . Platelet count &lt; 50,000/mm3 4 . AST ALT &gt; 5 time upper limit normal inclusive subject positive HBV surface antigen HCV antibody test screen 5 . Calculated creatinine clearance ( ClCr ) &lt; 40 mL/min determine CockcroftGault equation 6 . Subjects receive radiation therapy cytotoxic chemotherapeutic agent within 4 week prior first dose study drug . 7 . Subjects receive treatment immunomodulating agent IL2 , α IFN , β IFN γ IFN within 4 week prior first dose study drug . 8 . Subjects use require prohibit therapy within 30 day prior participate study . 9 . Receipt investigational drug product , participation drug study within period 30 day prior receive study medication . For investigational drug elimination half life great 10 day , period extend 60 day antibodybased product ( i.e. , CD4 antibody product , etc . ) period extend 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Sexually Transmitted Diseases , Viral</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Slow Virus Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Sexually Transmitted Diseases</keyword>
	<keyword>Lentivirus Infections</keyword>
	<keyword>Infection</keyword>
	<keyword>Retroviridae Infections</keyword>
	<keyword>Immunologic Deficiency Syndromes</keyword>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
	<keyword>bevirimat</keyword>
</DOC>